Regenxbio, Moderna and Others
Regenxbio (RGNX) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II
This content is for paid subscribers.
Today’s Highlights
January 30, 2020
